Granules India Limited

57.3%

, 3 8 8 8 , 9 9 4 8 , 3 9 9 7 , 9 3 0 5 , 7 0 6 4 , 7 1 5 4 , 8 4 6 4 , 8 7 5 4 , 57.3% 54.2% 50.9% 48.9% 46.6% 0 2 0 2 , 4 1 0 2 , 25.3% 23.7% 25.1% 2 1 5 1 , 17.0% 7 3 7

54.2%

8 8 , 9 9 4 8 , 3 9 9 7 , 9 3 0 5 , 7 0 6 4 , 7 1 5 4 , 8 4 6 4 , 8 7 5 4 , 57.3% 54.2% 50.9% 48.9% 46.6% 0 2 0 2 , 4 1 0 2 , 25.3% 23.7% 25.1% 2 1 5 1 , 17.0% 7 3 7 1 , 7

50.9%

9 9 4 8 , 3 9 9 7 , 9 3 0 5 , 7 0 6 4 , 7 1 5 4 , 8 4 6 4 , 8 7 5 4 , 57.3% 54.2% 50.9% 48.9% 46.6% 0 2 0 2 , 4 1 0 2 , 25.3% 23.7% 25.1% 2 1 5 1 , 17.0% 7 3 7 1 , 7 2 9 1

48.9%

8 , 3 9 9 7 , 9 3 0 5 , 7 0 6 4 , 7 1 5 4 , 8 4 6 4 , 8 7 5 4 , 57.3% 54.2% 50.9% 48.9% 46.6% 0 2 0 2 , 4 1 0 2 , 25.3% 23.7% 25.1% 2 1 5 1 , 17.0% 7 3 7 1 , 7 2 9 1 , 18.

46.6%

3 9 9 7 , 9 3 0 5 , 7 0 6 4 , 7 1 5 4 , 8 4 6 4 , 8 7 5 4 , 57.3% 54.2% 50.9% 48.9% 46.6% 0 2 0 2 , 4 1 0 2 , 25.3% 23.7% 25.1% 2 1 5 1 , 17.0% 7 3 7 1 , 7 2 9 1 , 18.5% 17.

25.3%

, 7 1 5 4 , 8 4 6 4 , 8 7 5 4 , 57.3% 54.2% 50.9% 48.9% 46.6% 0 2 0 2 , 4 1 0 2 , 25.3% 23.7% 25.1% 2 1 5 1 , 17.0% 7 3 7 1 , 7 2 9 1 , 18.5% 17.4% 17.4% Q4FY21 Q1FY22 Q2FY22

23.7%

1 5 4 , 8 4 6 4 , 8 7 5 4 , 57.3% 54.2% 50.9% 48.9% 46.6% 0 2 0 2 , 4 1 0 2 , 25.3% 23.7% 25.1% 2 1 5 1 , 17.0% 7 3 7 1 , 7 2 9 1 , 18.5% 17.4% 17.4% Q4FY21 Q1FY22 Q2FY22 Q3FY22

25.1%

, 8 4 6 4 , 8 7 5 4 , 57.3% 54.2% 50.9% 48.9% 46.6% 0 2 0 2 , 4 1 0 2 , 25.3% 23.7% 25.1% 2 1 5 1 , 17.0% 7 3 7 1 , 7 2 9 1 , 18.5% 17.4% 17.4% Q4FY21 Q1FY22 Q2FY22 Q3FY22 Q4FY22

17.0%

5 4 , 57.3% 54.2% 50.9% 48.9% 46.6% 0 2 0 2 , 4 1 0 2 , 25.3% 23.7% 25.1% 2 1 5 1 , 17.0% 7 3 7 1 , 7 2 9 1 , 18.5% 17.4% 17.4% Q4FY21 Q1FY22 Q2FY22 Q3FY22 Q4FY22 Q4FY21 Q1FY22 Q2F

18.5%

.9% 46.6% 0 2 0 2 , 4 1 0 2 , 25.3% 23.7% 25.1% 2 1 5 1 , 17.0% 7 3 7 1 , 7 2 9 1 , 18.5% 17.4% 17.4% Q4FY21 Q1FY22 Q2FY22 Q3FY22 Q4FY22 Q4FY21 Q1FY22 Q2FY22 Q3FY22 Q4FY22 Q4FY21 Q1FY2

17.4%

.6% 0 2 0 2 , 4 1 0 2 , 25.3% 23.7% 25.1% 2 1 5 1 , 17.0% 7 3 7 1 , 7 2 9 1 , 18.5% 17.4% 17.4% Q4FY21 Q1FY22 Q2FY22 Q3FY22 Q4FY22 Q4FY21 Q1FY22 Q2FY22 Q3FY22 Q4FY22 Q4FY21 Q1FY22 Q2FY2

16.3%

from Operations (Rs. Mn.) Gross margin and margin% (Rs. Mn.) EBITDA and EBITDA margins (Rs. Mn.) 16.3% 37,649 32,375 57.0% 18463 50.0% 18813 20000 19500 19000 18500 18000 17500 17000 165

Total GPI products include

1

Corporate address

1

Total GPI products include

ANDA/Dossier filed - Therapeutic area wise CII – 7 PFOS – 4 Liquid Orals – 3 IMS value for these products is approximately $9,229 Mn *Source IMS MAT Nov 2021 Analgesics Central Nervous… Anti-diabetics Mineral supplements 5 Cardiovasculars Anti Histamines 4 Anti gout Antitussives Other areas 3 3 8 7 10 21 18 8 Revenue trend – percentage share from Core and Other Molecules Core Others Para MF IBU GGF MCB Others 14% 14% 17% 14% 15% 17% 16% 15% 19% 16% 86% 86% 83% 86% 85% 83% 84% 85% 81% 84% 14% 34% 1% 5% 17% 29% 33% 17% 26% 6% 4% 19% 21% 21% 34% 29% 34% 34% 33% 30% 15% 18% 5% 3% 25% 19% 23% 17% 29% 14% 16% 3% 3% 3% 18% 19% 3% 16% 3% 3% 13% 6% 26% 25% 17% 4% 5% 5% 1% 14% 34% 38% 3% 14% FY18FY18FY18FY18 FY19FY19FY19FY19 FY20FY20FY20FY20 FY21FY21FY21FY21 FY22FY22FY22FY22 FY18 FY19 FY20 FY21 FY22 Core includes Paracetamol, Metformin, Ibuprofen, Methocarbamol and Guaifenesin 9 5-year trajectory: Key Ratios and Cash Flow Net Debt & Net debt-to-EBITDA (x) Cash-to-Cash cycle (days) Free Cash Flow

Corporate address

Floor 2 Block 3 My Home Hub Madhapur Hyderabad 500081 CIN: L24110TG1991PLC012471 Voice: +91 40 69043600 Fax: +91 40 69043602 www.granulesindia.com 532482 GRANULES GRAN:IN GRAN:NS